Critical Comparison: Elicio Therapeutics (ELTX) and Its Rivals

Elicio Therapeutics (NASDAQ:ELTX) is one of 610 publicly-traded companies in the “MED – BIOMED/GENE” industry, but how does it compare to its competitors? We will compare Elicio Therapeutics to similar companies based on the strength of its profitability, dividends, earnings, valuation, analyst recommendations, risk and institutional ownership.

Earnings and Valuation

This table compares Elicio Therapeutics and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Elicio Therapeutics	N/A	-$39.57 million	-5.59
Elicio Therapeutics Competitors	$903.00 million	$76.47 million	-28.78

Elicio Therapeutics’ competitors have higher revenue and earnings than Elicio Therapeutics. Elicio Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings and target prices for Elicio Therapeutics and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1	0	2	1	2.75
Elicio Therapeutics Competitors	8576	13260	40559	1399	2.55

Elicio Therapeutics currently has a consensus target price of $18.00, indicating a potential upside of 34.18%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 65.52%. Given Elicio Therapeutics’ competitors higher probable upside, analysts plainly believe Elicio Therapeutics has less favorable growth aspects than its competitors.

Profitability

This table compares Elicio Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-2,748.16%	-151.12%
Elicio Therapeutics Competitors	-809.33%	-698.34%	-27.95%

Institutional & Insider Ownership

35.0% of Elicio Therapeutics shares are owned by institutional investors. Comparatively, 51.3% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 50.9% of Elicio Therapeutics shares are owned by company insiders. Comparatively, 12.4% of shares of all “MED – BIOMED/GENE” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Elicio Therapeutics has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, Elicio Therapeutics’ competitors have a beta of 1.10, meaning that their average share price is 10% more volatile than the S&P 500.

Summary

Elicio Therapeutics competitors beat Elicio Therapeutics on 7 of the 13 factors compared.

About Elicio Therapeutics

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.